One more step toward treatment of PARP inhibitor-resistant ovarian cancers
A new editorial paper titled "One more step toward treatment of PARP inhibitor-resistant ovarian cancers" has been published in Oncotarget.
Jan 10, 2024
0
2
A new editorial paper titled "One more step toward treatment of PARP inhibitor-resistant ovarian cancers" has been published in Oncotarget.
Jan 10, 2024
0
2
The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression two years after discontinuing treatment, ...
Dec 18, 2023
0
2
A new study finds that radiation therapy (RT) suppresses a key protein called bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) and activates immune suppressive cells. These effects dampen the capacity ...
Dec 15, 2023
0
0
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers ...
Dec 14, 2023
0
0
A new study, published online ahead of print in Journal for ImmunoTherapy of Cancer on December 6, has identified a novel biomarker for ICIs in human cancers.
Dec 13, 2023
0
12
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), ...
Dec 12, 2023
0
0
CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities.
Dec 11, 2023
0
10
New research in the December 2023 issue of Journal of the National Comprehensive Cancer Network finds that patients treated with first-line immunotherapy for advanced non-small cell lung cancer (NSCLC) showed similar results ...
Dec 11, 2023
0
0
Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the San Antonio Breast ...
Dec 8, 2023
0
0
For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a significant benefit over chemotherapy, according ...
Dec 7, 2023
0
0